Skye Bioscience Croissance future
Future contrôle des critères 0/6
Skye Bioscience's earnings are forecast to decline at 26.8% per annum. EPS is expected to decline by 13% per annum.
Informations clés
-26.8%
Taux de croissance des bénéfices
-13.0%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 27.1% |
Taux de croissance des recettes | n/a |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Good |
Dernière mise à jour | 30 Sep 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | N/A | -52 | -46 | -33 | 4 |
12/31/2025 | N/A | -40 | -25 | -26 | 6 |
12/31/2024 | N/A | -31 | -27 | -22 | 6 |
6/30/2024 | N/A | -42 | -20 | -20 | N/A |
3/31/2024 | N/A | -37 | -15 | -15 | N/A |
12/31/2023 | N/A | -38 | -14 | -14 | N/A |
9/30/2023 | N/A | -43 | -15 | -15 | N/A |
6/30/2023 | N/A | -21 | -13 | -13 | N/A |
3/31/2023 | N/A | -22 | -14 | -14 | N/A |
12/31/2022 | N/A | -19 | -13 | -13 | N/A |
9/30/2022 | N/A | -12 | -10 | -10 | N/A |
6/30/2022 | N/A | -11 | -9 | -9 | N/A |
3/31/2022 | N/A | -9 | -8 | -8 | N/A |
12/31/2021 | N/A | -9 | -7 | -6 | N/A |
9/30/2021 | N/A | -8 | -6 | -6 | N/A |
6/30/2021 | N/A | -7 | -7 | -7 | N/A |
3/31/2021 | N/A | -6 | -6 | -6 | N/A |
12/31/2020 | N/A | -7 | -6 | -6 | N/A |
9/30/2020 | N/A | 0 | -6 | -6 | N/A |
6/30/2020 | N/A | -4 | -5 | -5 | N/A |
3/31/2020 | N/A | 13 | -6 | -6 | N/A |
12/31/2019 | N/A | 1 | -6 | -6 | N/A |
9/30/2019 | N/A | -10 | -6 | -6 | N/A |
6/30/2019 | N/A | -7 | -5 | -5 | N/A |
3/31/2019 | N/A | -26 | -4 | -4 | N/A |
12/31/2018 | N/A | -19 | -4 | -4 | N/A |
9/30/2018 | N/A | -14 | -5 | -5 | N/A |
6/30/2018 | N/A | -12 | -4 | -4 | N/A |
3/31/2018 | N/A | -10 | N/A | -4 | N/A |
12/31/2017 | N/A | -4 | N/A | -3 | N/A |
9/30/2017 | N/A | -5 | N/A | -2 | N/A |
6/30/2017 | N/A | -5 | N/A | -2 | N/A |
3/31/2017 | N/A | -4 | N/A | -3 | N/A |
12/31/2016 | N/A | -4 | N/A | -4 | N/A |
9/30/2016 | N/A | -3 | N/A | -4 | N/A |
6/30/2016 | N/A | -3 | N/A | -5 | N/A |
3/31/2016 | N/A | -6 | N/A | -4 | N/A |
12/31/2015 | N/A | -5 | N/A | -4 | N/A |
9/30/2015 | N/A | -6 | N/A | -3 | N/A |
6/30/2015 | N/A | -6 | N/A | -3 | N/A |
3/31/2015 | N/A | -4 | N/A | -3 | N/A |
12/31/2014 | N/A | -3 | N/A | -2 | N/A |
9/30/2014 | N/A | -1 | N/A | -1 | N/A |
6/30/2014 | N/A | 0 | N/A | 0 | N/A |
3/31/2014 | N/A | 0 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: SKYE is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: SKYE is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: SKYE is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: Insufficient data to determine if SKYE's revenue is forecast to grow faster than the US market.
Croissance élevée des revenus: SKYE is forecast to have no revenue next year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if SKYE's Return on Equity is forecast to be high in 3 years time